China's humanoid robots will not replace human workers: Official
BEIJING: China's humanoid robots will not replace human workers and cause mass unemployment, according to a Chinese official who oversees a tech hub in Beijing, amid a rapid expansion of the sector and state funding for it.
Liang Liang, a deputy director at the Beijing Economic-Technological Development Area, which hosts one of China's largest tech hubs, said in an interview on Friday (May 16) with foreign media that he does not believe that humanoid robots will replace their human creators, but will boost productivity and operate in hazardous environments.
"We don't believe robots will make people unemployed, but rather they'll boost efficiency or take on tasks humans are unwilling to do - like exploring the vast universe or the ocean depths where people can't go. Machines can assist us in that exploration," Liang said.
"When it's nighttime and humans need rest, machines could keep working, giving us better, cheaper and more user-friendly products. So we see this as the direction for our future development," he added.
Liang explained that the world's first robot half-marathon held last month in Beijing was deliberately set up in a way that would highlight his and other officials' hopes that these humanoids will support and assist humans, rather than replace them.
The half-marathon featured two tracks separated by a railing, with humans competing against each other on one side while on the other side 20 teams each operated a robot, varying wildly in size and ability.
"You see, in the marathon, humans have their track where they push their physical limits, and the machines have their own track where they jointly challenge their limits - but they aren't trying to take over the human course to sprint to the finish line. The future will be like this too," Liang said.
Liang spoke to reporters at the headquarters of state-backed X-Humanoid, also known as the Beijing Humanoid Robotics Innovation Centre, whose robot Tiangong Ultra won the inaugural robot half-marathon.
Besides the sports-focused Ultra model, which can reach a top speed of 12kmh, the centre also displayed other protypes that showed it was working on robots that can complete mundane tasks in the face of obstructions and changing environments.
In one demonstration, an employee repeatedly moved the position of a piece of litter or snatched it from the robot's hand, which would then relocate the object and carry out the task until it was completed, a self-corrective ability the centre says will be key in turning the humanoids into productive workers.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Times
2 hours ago
- Business Times
China's biotech moment ignites a 60% stock rally that beats AI
China's biotechnology stocks have shaken off a four-year slump to be among the hottest performers in Asia this year and funds are tipping further gains. The Hang Seng Biotech Index has surged more than 60 per cent since the start of January amid investor enthusiasm over a pair of billion-dollar deals involving foreign firms licensing Chinese drugs. Share gains at two highly anticipated listings of local producers have further burnished the sector's appeal. 'China biotech is no longer just an emerging story – unlike 10 years ago – it is now a disruptive force reshaping global drug innovation,' said Yiqi Liu, senior investment analyst at Exome Asset Management in New York. 'The science is real, the economics are compelling, and the pipeline is starting to deliver.' The surge in China-listed biotech firms is further evidence that the mainland is becoming a centre for global innovation. The rally in the sector this year outpaces the 17 per cent gain in China's tech stocks that was driven by the release of DeepSeek's breakthrough artificial-intelligence app in January. A major reason for the share gains were two mega-sized licensing deals. Pfizer said on May 19 that it had agreed to pay a record US$1.25 billion to license an experimental cancer drug from China's 3SBio, and also invest US$100 million in the firm's shares. Two weeks later, Bristol-Myers Squibb said it would pay Germany's BioNTech as much as US$11.5 billion to license a cancer drug that BioNTech had itself licensed from China's Biotheus in 2023. Some of the gains in biotech shares this year have been stratospheric. 3SBio has surged 283 per cent, topping a Bloomberg gauge of global biotech stocks. RemeGen, which develops antibody drugs, has climbed more than 270 per cent after saying it was approached by multinational pharmaceutical firms for potential licensing deals. BT in your inbox Start and end each day with the latest news stories and analyses delivered straight to your inbox. Sign Up Sign Up China's growing influence through pharmaceutical mergers and acquisitions and deal-making is also causing investors to take note. In the first quarter alone, the value of such deals involving local players doubled from the year before to US$36.9 billion. That amount made up more than half the global total of US$67.5 billion. Chinese biotech companies are having 'their own DeepSeek moment', said Dong Chen, chief Asia strategist at Pictet Wealth Management in Hong Kong. There is more upside from here, he said. Investor interest in biotech – which involves the use of living organisms to make medicines and other products – can be seen in the big runup at recent initial public offerings. Shares of Duality Biotherapeutics, which develops cancer treatments, more than doubled on their first day of trading in Hong Kong on Apr 15. Jiangsu Hengrui Pharmaceuticals, the nation's largest drugmaker by market value, saw its stock jump 25 per cent on its May 23 debut, even after being issued at the top end of the marketed range. Duality has now risen 189 per cent since its IPO, while Jiangsu has gained 31 per cent. Still, some say the rally may be getting stretched. 'Bears, mostly healthcare specialists, plan to take profit at this point, and some investors prefer the healthcare laggers with capability of constant dividend payout and stable revenue growth,' Bank of America analysts including Ethan Cui in Hong Kong wrote in a research note this month. Some investors also said they viewed the rush of recent licensing deals as a one-off, and they were refusing to grant valuation multiples to the companies, the analysts wrote. Talent returns While the recent ratcheting up of trade tensions between the US and China has been a negative for many mainland firms, it's also resulted in talent flowing back to China and creating more research-and-development capability, according to Nicholas Chui, a Chinese equity fund manager at Franklin Templeton in Hong Kong. Jefferies is also bullish, saying the increase in US tariffs is unlikely to prove an obstacle to Chinese biotech firms. Many of the Chinese biotech companies already have US partners and are therefore considered as service providers rather than product exporters, said Cui Cui, head of Asia healthcare research at the company in New York. BLOOMBERG
CNA
2 hours ago
- CNA
Hong Kong trade body plans 2026 conference to entice Gulf states
HONG KONG: The Hong Kong Trade Development Council (HKTDC) plans to host a conference next year to foster collaboration with Gulf states, the body's new head has said, adding that US President Donald Trump's unpredictable policies could result in further changes to its export projections. Frederick Ma Si-hang, who took office on June 1, also said on Sunday that the council was exploring the feasibility of organising exhibitions at government venues to address an ongoing shortage of event spaces. On the subject of Trump, he said the unpredictability of the United States president's policies had led to a slowdown in investment growth globally and could result in further adjustments to the council's export projections for the city. The body earlier lowered its 2025 export growth forecast for Hong Kong from 4 per cent to 3 per cent. The former treasury minister said the city needed to revive and strengthen its historical role as a connector for trade, while noting he was the first Hong Kong official to lead a delegation to the Middle East in 2006. Ma said that the city's trade with South Asian and Middle Eastern countries had grown by more than 30 per cent in recent years, with investors from those regions becoming increasingly active. 'I am going to do something about this: I hope there will be a conference held in Hong Kong next year focusing on the Gulf Cooperation Council countries,' he told a television programme. 'We will gather friends from the Middle East, mainland China and Southeast Asia, and of course, companies in Hong Kong.' Ma also spoke about challenges arising from the city's lack of conference and exhibition venues, explaining that even with the creation of more locations under the North Metropolis mega-project, such initiatives could take up to a decade to finish. 'Building new exhibition spaces in the Northern Metropolis is not simple … Without access to the MTR, (event) attendance will be low,' he said. 'We must look for immediate solutions, such as collaborating with organisations to host exhibitions at their venues, including certain government sites.' 46:50 Min Ma also said he was reviewing the HKTDC's network of 51 overseas offices and stressed the importance of efficiently utilising resources, especially in light of the government's financial deficit. While he said no final decisions had been made, he confirmed the number of offices on the mainland would remain the same. 'The 13 offices in mainland China are crucial for connecting local enterprises with international markets, serving a role that other places cannot fulfil,' he said. In a separate appearance on a radio programme, Ma said he had tasked his team with identifying emerging markets suitable for trading with Hong Kong. Some African countries were being considered by the council due to their large populations and strong economic development, he said. The former minister said the council could explore the potential for growth there and provide help in terms of supply and industrial chains to small-to-medium-sized enterprises interested in the area. Ma also said he was glad that former Morgan Stanley Asia chairman Stephen Roach had recently 'changed his stance' after declaring last year that the city was 'over'. In an interview with the Post this month, Roach said the city had benefited from the crossfire between the US and China, but claimed that other aspects of the financial hub had worsened. Ma on Sunday said: 'If Hong Kong can maintain its advantages, such as its legal system, financial stability, talent and a free flow of capital, among others, Hong Kong will definitely not be over.' 'Now, we are proved correct … As the world changes, many people will consider coming to Hong Kong. The Hong Kong stock market has been buoyant, and we see vibrancy in the economy. I hope we can capitalise on our strengths to do well.'
Straits Times
4 hours ago
- Straits Times
Taiwan adds China's Huawei, SMIC to export control list
Semiconductor Manufacturing International Corporation has been added to Taiwan's export control list along with Huawei Technologies. PHOTO: REUTERS TAIPEI - Taiwan's government has added China's Huawei Technologies and Semiconductor Manufacturing International Corp (SMIC) to its export control list, which includes other proscribed organisations like the Taliban and al Qaeda. Inclusion on the economy ministry's trade administration's strategic high-tech commodities entity list means Taiwanese companies will need government approval before exporting any products to the companies. The companies were included in an updated version of the ministry's trade administration's website late on June 14 . Neither company nor the economy ministry immediately responded to requests for comment outside of office hours at the weekend. Taiwan is home to TSMC, the world's largest contract chipmaker and a major supplier of chips to AI darling Nvidia. Both Huawei and SMIC have been working hard to catch up in the chip technology race. Taiwan, which China claims as its own territory despite the strong objections of Taipei's government, already has tight chip export controls when it comes to Taiwanese companies either manufacturing in the country or supplying Chinese firms. Huawei, which is at the centre of China's AI ambitions, is on a US Commerce Department trade list that essentially bars it from receiving US goods and technology, as well as foreign-made goods such as chips from companies like TSMC made with US technology. In October 2024, TechInsights, a Canadian tech research firm, took apart Huawei's 910B AI processor and found a TSMC chip in it. The multi-chip 910B is viewed as the most advanced AI accelerator mass-produced by a Chinese company. TSMC suspended shipments to China-based chip designer Sophgo, whose chip matched the one in the Huawei 910B and, in November 2024, the US Commerce Department ordered TSMC to halt shipments of more chips to Chinese customers. Taiwan's government has also repeatedly vowed to crack down on what it says are efforts by Chinese companies, including SMIC, to steal technology and entice chip talent away from the island. SMIC is China's largest chipmaker and has ramped up investment to expand production capacity and strengthen China's domestic semiconductor capability in the face of sweeping US export controls. REUTERS Join ST's Telegram channel and get the latest breaking news delivered to you.
